Claudin-1 / egfr bispecific antibodies

TW202631671APending Publication Date: 2026-08-01ALENTIS THERAPEUTICS AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114135010
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-09-12
Filing Date
2025-09-11
Publication Date
2026-08-01

Smart Images

  • Figure TWG2TA001070403_001
    Figure TWG2TA001070403_001
  • Figure TWG2TA001070403_002
    Figure TWG2TA001070403_002
  • Figure TWG2TA001070403_003
    Figure TWG2TA001070403_003
Patent Text Reader

Abstract

This disclosure relates to bispecific antibodies that bind to ligand 1 and EGFR and their use in the treatment of diseases (e.g., cancer). The present disclosure relates to bispecific antibodies that bind Claudin 1 and EGFR and their use in treating diseases, for example, cancer.
Need to check novelty before this filing date? Find Prior Art